Login
ImageneBio, Inc. logo

ImageneBio, Inc.

imagenebio.com

What Do They Do?

Develops an antibody drug candidate for atopic dermatitis and other autoimmune and inflammatory diseases.

How Do They Make Money?

The company earns money from licensing its intellectual property and collaborating with other companies. Agreements can provide upfront payments, research and development funding, milestone payments, and royalties on sales of approved products.

FY2025 revenue

Who Are Their Customers?

Other companies enter licensing and collaboration agreements for the company's intellectual property and for research, development and commercialization activities.

Do Revenues Turn Into Profits?

No. It lost $45.3M in FY2025.

Operating income, FY2025
−6056% of revenue
▼ −31% (Loss) vs FY2024 (−$37M, −1057%)
Net income, FY2025
−5669% of revenue
▼ −24% (Loss) vs FY2024 (−$36.6M, −1045%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +37% (Loss)
vs −$24.8M in Q3 FY2025
  • Jul 20, 2026 Appointed a new chief financial officer

Shrinking. Revenue fell 97% in 4 years, from $31M in FY2021 to $800K in FY2025, about 60% a year.

From oncology to inflammatory disease The older report centered on targeted cancer medicines for biomarker-defined tumors, including programs across the Hippo, RAS and immune-signaling pathways. The latest report focuses on a therapeutic for autoimmune and inflammatory diseases, initially atopic dermatitis.

Who Do They Compete With?

Competes with Sanofi/Regeneron, Leo Pharmaceuticals, Eli Lilly, Galderma Laboratories, Pfizer, AbbVie, Nektar Therapeutics, Apogee Therapeutics, Kymera Therapeutics, Aclaris Therapeutics, Corvus Pharma, UCB Pharma, Sanofi, Amgen, Kyowa Kirin, Abcellera, Astria, BioCryst, and Navigator Medicines

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support